Drugs / fructooligosaccharide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06793514 | Feb → May 2025 overdue | dry eye syndrome | Mohsen Pourazizi | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00343642 | Sep 2006 → Oct 2012 | Crohn disease | Rush University Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fructooligosaccharide | “The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium...” NCT06793514 ↗2“a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects” NCT00343642 ↗ |
| Known as | FOS | “The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium...” NCT06793514 ↗1“a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects” NCT00343642 ↗ |
| Route | Oral | “administered orally” NCT00343642 ↗ |